News/ News/ R&D/ Top stories Novartis keeps a close eye on gene therapy with Vedere Bio buy Phil Taylor gene therapy, M&A, Novartis, ophthalmology, Vedere Bio 0 Comment Already a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 Share X Novartis keeps a close eye on gene therapy with Vedere Bio buy https://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/
gene therapy, M&A, Novartis, ophthalmology, Vedere Bio
0 Comment
